Named Supplier on NHSX Procurement Framework
28 August 2020, 17:49 UTC By inhc
28 August 2020, 17:49 UTC By inhc
28 August 2020
Induction Healthcare Group PLC
(“Induction”, the “Company”, or the “Group”)
Induction Switch named Supplier on NHSX Clinical Communications Procurement Framework
Induction Healthcare, a leading healthcare technology company that helps healthcare professionals deliver better care more efficiently, today announces that its Induction Switch platform has been awarded the status of Supplier on the Clinical Communications Procurement Framework run by the National Commercial and Procurement Hub on behalf of NHSX, a joint unit dedicated to driving forward the digital transformation of care in the UK.
The Procurement Framework has been established to support NHS organisations by providing clinicians with access to a wide range of dedicated clinical facing communication and task management tools to accelerate the adoption of proven technologies. The Framework has been granted £3 million of government funding to aid the move towards more modern forms of communication and to phase out pagers by the end of 2021.1 The Framework is scheduled to run from 3 August 2020 to 3 August 2022, with a possible extension of a further 12 months.2
Induction Healthcare products are routinely used by hundreds of thousands of NHS staff and patients, and have been heavily relied upon during the COVID-19 pandemic to deliver care under challenging conditions. The inclusion of Induction Switch on this framework provides strong validation of the Company’s high standards of Clinical Safety, Data Security and Information Governance, further supported by the Company’s ISO 27001, ISO 9001, Cyber Essentials, and NHS DSPT certifications.
Hugo Stephenson, joint CEO of Induction, commented: “We are proud to have been selected for the NHSX Clinical Communications Procurement Framework and are confident it will enable easier access to clinical facing communication and task management tools used by hundreds of thousands of NHS staff across the UK on a daily basis. This success highlights, once again, the strength of Induction’s technology and its commitment to improve the delivery of care.”
As the procurement framework has now been officially launched, the Company expects procurement activity across the NHS to begin in the near future.
|Induction Healthcare||Via FTI Consulting|
|Dr Hugo Stephenson, Joint Chief Executive Officer|
|James Balmain, Joint Chief Executive Officer|
|Numis Securities (Nominated Adviser and Broker)||+44 (0) 207 260 1000|
|James Black / Freddie Barnfield / Huw Jeremy / Matthew Jones|
|FTI Consulting||+44 (0) 203 727 1000|
|Jamie Ricketts / Elena Kalinskaya / Sam Purewal / Mary Whittow|
Induction Healthcare Group PLC is a leading healthcare technology company that helps healthcare professionals deliver better care more efficiently. The Group has three platforms, Induction, MicroGuide, and Zesty that support healthcare professionals in multiple markets, including the UK, Ireland, Australia & South Africa, plus Zesty, a leading provider of patient portals to NHS Hospitals in the UK.
Induction is the number one healthcare collaboration app in the UK, used by the majority of hospital doctors within the NHS. The app helps over 140,000 registered users in multiple territories to increase productivity and enhance communication by securely sharing phone numbers and bleeps, bookmarks, documents and messages in a clinical setting.
The MicroGuide platform provides medical organisations with the ability to collaboratively create, edit, and publish their own local medical guidelines in a secure and locally administrated environment. The platform helps over 170,000 registered users in multiple territories, including the majority of hospital trusts within the NHS.
The Zesty platform enables patients to manage their care direct from their smartphone. The Zesty patient portal removes the friction from everyday health related tasks, like booking and managing appointments, reading letters digitally and sharing copies of electronic medical records.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact email@example.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Private Policy.